Joshua K. Sabari, MD, is an associate professor in the Department of Medicine at New York University (NYU) Grossman School of Medicine. He is also medical director, ofThoracic Medical Oncology at NYU Langone Health’s Perlmutter Cancer Center.
Panelists discuss how medical professionals identify patients who should receive neoadjuvant immune checkpoint inhibitors (ICI) before surgery based on tumor characteristics, patient health, and treatment response, and how factors such as surgical outcomes, recurrence risk, and molecular markers guide decisions on the need for additional adjuvant therapy post surgery.
Panelists discuss how the latest efficacy and safety data from AEGEAN, CheckMate 816, CheckMate 77T, and KEYNOTE-671, along with recent approvals in early-stage non–small cell lung cancer (NSCLC) treatment, are shaping optimized treatment approaches and influencing clinical practice.
Panelists discuss how a multidisciplinary team—including oncologists, thoracic surgeons, radiologists, and pathologists—collaborates to streamline the diagnostic process for patients with resectable non–small cell lung cancer (NSCLC), ensuring timely evaluation, accurate staging, and personalized treatment planning.
Panelists discuss how a multidisciplinary team (MDT) approach to resectable non–small cell lung cancer (NSCLC) involves an initial diagnostic workup with imaging (CT, PET-CT), histologic confirmation via biopsy, staging with mediastinal assessment (endobronchial ultrasound or mediastinoscopy), and timely molecular testing (eg, EGFR, ALK, PD-L1) integrated early in the process to guide perioperative treatment decisions.
Panelists discuss how a multidisciplinary approach enhances the early diagnosis of non–small cell lung cancer (NSCLC) by integrating insights from oncology, radiology, pathology, and surgery.
Panelists discuss how comprehensive biomarker testing in early-stage disease settings provides crucial molecular insights that guide surgical planning and inform critical decisions about neoadjuvant, perioperative, and adjuvant treatment strategies.
Panelists discuss how collaboration between pathologists, oncologists, and pulmonologists is essential for timely next-generation sequencing (NGS) testing in early-stage non–small cell lung cancer (NSCLC), emphasizing that molecular testing should ideally be ordered at diagnosis with prioritization of EGFR, ALK, ROS1, BRAF, MET, KRAS, RET, and NTRK biomarkers to guide treatment decisions before surgical intervention.
Panelists discuss how medical professionals frequently encounter tissue adequacy challenges in comprehensive genomic profiling for early-stage non–small cell lung cancer (NSCLC), employing strategies such as optimized biopsy techniques, efficient tissue triage protocols, and complementary liquid biopsies to ensure sufficient material for complete molecular analysis.
Panelists discuss how medical professionals currently approach molecular testing in early-stage non–small cell lung cancer (NSCLC) through comprehensive biomarker analysis, including targeted next-generation sequencing (NGS), to identify actionable mutations that guide adjuvant therapy decisions and improve patient outcomes.
Joshua K. Sabari, MD, discusses key considerations when testing for HER2 alterations in non–small cell lung cancer
Joshua K. Sabari, MD, discusses FDA approval of first-line amivantamab plus lazertinib for locally advanced or metastatic EGFR-mutated non–small cell lung cancer.
The panel discusses treatment considerations for consolidation durvalumab.
The panel discusses data necessary for selecting patients with unrespectable non–small cell lung cancer for sequential vs concurrent chemoradiotherapy.
The panel looks at a second patient case study.
The panel discusses management of resectable early-stage non–small cell lung cancer.
The panel discusses the factors that go into selecting patients for adjuvant therapy.
The panel discusses reassessing for respectability after certain treatments.
Joshua K. Sabari, MD, discusses barriers to biomarker testing in patients with non–small cell lung cancer.
A variety of treatment options in ES NSCLC are explored by key opinion leaders.
The panel discusses a variety of clinical trials and the impact on patient treatment in early stage NSCLC.
Panelists discuss the utilization of testing and multidisciplinary approaches for testing.
Medical experts discuss a specific case for a patient diagnosed with stage IIIB NSCLC.
Joshua K. Sabari, MD, discusses the FDA approval of frontline amivantamab plus chemotherapy for NSCLC harboring EGFR exon 20 insertion mutations.
Joshua K. Sabari, MD, reviews data from the 5-year overall survival update from the POSEIDON study investigating durvalumab, tremelimumab, and chemotherapy in first-line metastatic non–small cell lung cancer.
Joshua K. Sabari, MD, discusses the investigation of patritumab deruxtecan in EGFR-mutant non–small cell lung cancer.
The expert panel closes its discussion with advice for community physicians and discusses the future treatment landscape for advanced non–small cell lung cancer.
In closing, experts share future perspectives in KRAS G12C-mutated NSCLC, emphasizing novel targeted therapies and emerging trials in the evolving treatment landscape.
Shared insight on the clinical management of hepatotoxicity with use of KRAS G12C inhibitors in mNSCLC.
The panel discusses the use of antibody-drug conjugates for patients with EGFR-mutant non–small cell lung cancer, with a focus on the HERTHENA-Lung01 and TROPION-Lung05 studies.
A panel of experts on non–small cell lung cancer provide their thoughts MARIPOSA-2, which studied amivantamab and chemotherapy in EGFR-mutant NSCLC in the second line and beyond.
